The “Smarter Monopoly” Debate Is Here—and It’s Not Just a Patent Story
Big Pharma has a new battleground: not just patents, but orphan drug exclusivity—a policy designed to incentivize treatments for rare diseases. The question now is whether that ince…
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents Read Post »
Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic Loss of Exclusivity
The most expensive mistake in biologics isn’t pricing—it’s timing.
In the sterile manufacturing world, the “cliff” is pred…
Generic competition isn’t just a legal event—it’s a business strategy.
For years, investors and policymakers have treated generic entry as a clean inflection point: patents expire, exclusivity ends, prices fall, and the market resets. But the reality…
Drug switching is the quiet question behind every “Is this safe?” search. Here’s what patients are really asking online.
If you’ve spent any time in healthcare, you’ve seen it: a prescription changes, a pharmacy substitutes, a payer denies, a manufactu…
Drug Switching Questions: What Patients Are Really Asking Online Read Post »
Evergreening isn’t a surprise—it’s a pattern. Patent intelligence is how you beat it.
In pharma, “brand” doesn’t just mean a product. It means a strategy.
For years, branded companies have used evergreening—incremental patent filings and lifecycle mana…
Pfizer’s Keytruda, also known as pembrolizumab, received initial FDA approval on September 4, 2014, for use in treating… https://www.Drugchatter.com/chat/37536/can-you-recall-the-initial-fda-approval-year-for-keytruda/
DrugChatter: Can you recall the initial fda approval year for keytruda? Read Post »
GPT, Rosalind, and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes
The life sciences industry has a habit of treating “AI” like a single invention—one breakthrough that will either fix everything or fail completely. But the real story…
GPT-Rosalind and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes Read Post »
Patent cliffs don’t just “happen.” They’re engineered—by timing, leverage, and payer behavior.
In pharma, the phrase patent cliff is often treated like weather: inevitable, disruptive, and largely outside your control. But the most effective companie…
Beat the Patent Cliff: How to Trigger Payer Strategy Campaigns Before Drug Patent LOE Read Post »
OpenAI’s GPT just did something that should make pharma lawyers sit up: it’s being credited with “smashing” drug patent cliffs—by accelerating the work that used to take teams months (or longer) to complete.
That’s the claim behind the latest buzz from…
OpenAI’s GPT-Rosalind = Smashed Drug Patent Cliffs and 70% Faster ANDAs Read Post »
According to the manufacturer’s information on DrugPatentWatch.com [1], Vascepa (icosapent ethyl) is an omega-3 fatty… https://www.Drugchatter.com/chat/21744/have-there-been-any-reported-adverse-effects-with-vascepa/
DrugChatter: Have there been any reported adverse effects with vascepa? Read Post »
Get new actionable insights and updates from BiotechBlog
